Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.

Jassin Rashidi-AlavijehKatja StraubAnne AchterfeldHeiner WedemeyerKatharina WilluweitKerstin Herzer

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2020)

Tenofovir alafenamide exhibits high antiviral efficacy and a good safety profile for LT recipients. Still, the safety and tolerability of TAF for organ transplant patients should be evaluated in larger cohorts.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
open label
randomized controlled trial
clinical trial
kidney transplantation